Xovoltib Afatinib Capsules (20 mg, 30 mg, 40 mg, 50 mg) (1 pack / 28 caps)

At a Glance

Generic Name: Afatinib (afatinib dimaleate)

Brand Name: Xovoltib

Strength & Pack Size: 20 mg, 30 mg, 40 mg, 50 mg per capsule; 1 pack / 28 capsules

Dosage Form & Route: Oral capsule, swallowed whole with water

Therapeutic Class: EGFR tyrosine kinase inhibitor (targeted anticancer therapy)

Primary Indication: EGFR mutation-positive non-small cell lung cancer (NSCLC) where afatinib is prescribed by an oncologist

Usual Adult Dose: Defined by an oncology specialist based on mutation status, prior therapy, and tolerability

Prescription Status: Prescription-only medicine

Storage: Store in original packaging as directed on the label; protect from moisture and keep out of reach of children

Product Description

Xovoltib contains afatinib, an oral targeted therapy used in adults with non-small cell lung cancer when EGFR mutation testing supports an EGFR-targeted approach and an oncology specialist determines that afatinib is appropriate. Xovoltib afatinib capsules are supplied as 1 pack / 28 caps and offered in multiple strengths (20 mg, 30 mg, 40 mg, 50 mg) to support individualized dosing within specialist-led care. Because this is prescription-only cancer therapy, treatment selection, monitoring, and any dose changes must be guided by a qualified oncologist.

Afatinib is commonly discussed in the context of EGFR inhibitor therapy for EGFR mutation-positive NSCLC. Your specialist considers the EGFR variant, prior treatments, organ function, comorbidities, and drug interactions before choosing therapy. Patients and caregivers following a prescription-led oncology plan may search for this treatment as Xovoltib afatinib capsules online when coordinating refills and maintaining continuity of care.

Generic Meds Mart supplies Xovoltib afatinib capsules in original packaging sourced through licensed channels. The carton typically includes clear labeling for strength, product name, active ingredient, batch number, and expiry date for verification by clinics and pharmacies. Orders are shipped in discreet outer packaging to support privacy, and global delivery options help patients coordinate access alongside required monitoring. If you are comparing afatinib price or evaluating EGFR inhibitor options, confirm the correct strength and pack size with your care team before ordering.

Key Uses

Xovoltib afatinib is used as EGFR-targeted therapy for non-small cell lung cancer in adults with confirmed EGFR mutation-positive disease, typically within a complete oncology care plan. Afatinib is a targeted tyrosine kinase inhibitor rather than a classic cytotoxic chemotherapy, and it requires monitoring for side effects, tolerability, and treatment response. The role of afatinib in NSCLC management depends on tumor characteristics, prior therapy exposure, and specialist judgment.

Common Searches and Treatment Contexts for Afatinib

• EGFR Inhibitor for NSCLC: Afatinib is used as a targeted EGFR tyrosine kinase inhibitor for EGFR mutation-positive non-small cell lung cancer under oncologist supervision.
• Afatinib Targeted Therapy: This medicine is used in treatment strategies where EGFR pathway blockade is expected to reduce growth signaling in defined NSCLC tumors.
• Afatinib 20 mg, 30 mg, 40 mg, 50 mg Capsules: Multiple strengths support individualized regimens and dose adjustment for tolerability when clinically needed.
• Buy Afatinib Online: Patients with a confirmed prescription and monitoring plan may seek reliable access to original-packaging afatinib to maintain therapy continuity.
• EGFR Mutation-Positive Lung Cancer Treatment: Afatinib is used when EGFR mutation testing indicates an EGFR-targeted approach is appropriate in NSCLC care.

How Afatinib Works in Chemotherapy

Afatinib works by irreversibly inhibiting the EGFR family of tyrosine kinases, which can drive tumor growth in certain NSCLC tumors with EGFR mutations. By blocking EGFR signaling, afatinib reduces downstream pathways that cancer cells may rely on for survival and proliferation. This targeted approach differs from traditional cytotoxic chemotherapy because it focuses on a specific molecular driver rather than broadly damaging dividing cells.

Because afatinib affects EGFR signaling in normal tissues as well as tumor cells, side effects often involve the skin and gastrointestinal tract. Your oncology team balances expected benefit with tolerability, and dose adjustment may be considered to manage symptoms while maintaining the treatment plan. Monitoring remains essential, and treatment decisions should follow specialist guidance.

Dosage & Administration

Xovoltib afatinib capsules must be taken exactly as prescribed by an oncologist. The selected strength (20 mg, 30 mg, 40 mg, or 50 mg) and schedule are individualized based on your clinical status, prior therapy, and tolerability. This is why afatinib dosage should never be changed without specialist instruction. Capsules should be swallowed whole with water and taken consistently according to the plan set by your clinic.

If you miss a dose, follow your prescribing team’s instructions rather than taking extra capsules to compensate. Drug interactions can be important, so share a complete list of medicines and supplements with your oncologist and pharmacist. Your team may also advise supportive care measures early, especially for diarrhea or skin reactions, to reduce the risk of complications and avoid unnecessary interruptions.

Precautions

Afatinib can cause significant diarrhea, which may become severe and lead to dehydration if not managed promptly. Skin reactions such as rash, dryness, and nail changes are common with EGFR inhibitors, and early management is often part of the care plan. Liver function changes can occur, so periodic blood tests may be required.

Rare but serious events can include interstitial lung disease-like reactions, severe skin reactions, ocular problems, or other clinically significant complications in susceptible patients. Pregnancy should be avoided during treatment, and contraception planning should be discussed with a qualified clinician. Report new or worsening shortness of breath, severe rash, eye pain, or persistent vomiting/diarrhea promptly.

Afatinib Side Effects

Common side effects

Common afatinib side effects include diarrhea, skin rash, dry skin, mouth sores, reduced appetite, nausea, fatigue, and nail changes. These effects can often be managed with supportive care and specialist-led dose adjustment. Do not self-adjust therapy; discuss symptoms early with your oncology team.

Serious side effects

Serious side effects require urgent medical attention and may include severe diarrhea with dehydration, severe skin reactions with blistering or peeling, new or worsening breathing problems that could suggest lung inflammation, significant liver injury signs such as jaundice or dark urine, or severe eye pain and vision changes. If you develop alarming symptoms, seek urgent care and inform clinicians that you are taking afatinib.

Storage

Store Xovoltib afatinib capsules in original packaging as directed on the label, protected from moisture and excessive heat. Keep out of reach of children. Do not use capsules after the expiry date printed on the carton.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access to specialist medicines such as Xovoltib afatinib capsules by supplying products in original packaging sourced through licensed channels. Clear labeling with batch and expiry information helps clinics and pharmacies verify each pack. Pricing is displayed in USD, and secure checkout supports straightforward ordering for planned therapy.

For patients coordinating ongoing EGFR-targeted therapy, discreet packaging and global delivery options can help maintain continuity alongside required monitoring. Generic Meds Mart does not replace your oncology team; all decisions about whether afatinib is suitable, how long to use it, and how to manage side effects must be made by qualified healthcare professionals.

Order Now

Before you buy Xovoltib afatinib capsules online from Generic Meds Mart, you should have confirmed EGFR mutation testing, a diagnosis of NSCLC, and a treatment plan defined by your oncologist. Your clinic will determine the appropriate strength (20 mg, 30 mg, 40 mg, or 50 mg), monitoring schedule, and supportive care plan. Once your plan is confirmed, select Xovoltib (1 pack / 28 caps), add it to your cart, and complete secure checkout in USD.

Do not start or change afatinib therapy without specialist supervision. If you develop severe diarrhea, breathing problems, jaundice, eye pain, or rapidly worsening rash, seek urgent medical care and inform clinicians that you are receiving afatinib.

FAQ about Xovoltib (Afatinib)

Q1: What is Xovoltib used for?
Xovoltib contains afatinib, an EGFR tyrosine kinase inhibitor used for EGFR mutation-positive non-small cell lung cancer when prescribed by an oncologist as part of a specialist-led plan.

Q2: How do I know which strength I need (20 mg, 30 mg, 40 mg, 50 mg)?
The strength is selected by your oncologist based on tolerability, monitoring, and the overall treatment plan. Multiple strengths allow dose adjustment when clinically needed.

Q3: Can I take Xovoltib at home?
Xovoltib is taken orally at home, but it is targeted cancer therapy that requires prescription-led monitoring and side effect management under oncology supervision.

Q4: What should I do if I miss a dose?
Follow your clinic’s instructions and do not take extra capsules to make up for a missed dose unless your oncologist specifically advises it. If unsure, contact your prescribing team.

Q5: What are common afatinib side effects?
Common afatinib side effects include diarrhea, skin rash, dry skin, mouth sores, reduced appetite, nausea, fatigue, and nail changes. Report persistent or severe symptoms early so your oncology team can guide supportive care.

Q6: Is Xovoltib the same as Gilotrif (Generic Gilotrif)?
Xovoltib is Generic Gilotrif – it contains the same active ingredient (afatinib) as Gilotrif. It’s used for the same purpose at the same strength, while differences may be in manufacturer, inactive ingredients (excipients), capsule appearance, and packaging. If you’re switching between products, confirm the substitution with a qualified healthcare professional.

Geftinat Gefitinib – 250 mg (1 pack / 30 tablets)

At a Glance

Generic Name: Gefitinib

Brand Name: Geftinat

Strength & Pack Size: Geftinat 250 mg tablets – 1 pack / 30 tablets

Dosage Form: Oral film-coated tablets

Therapeutic Class: EGFR tyrosine kinase inhibitor, targeted anticancer therapy

Main Indication: Advanced or metastatic non-small cell lung cancer (NSCLC) with sensitising EGFR mutations

Use in Therapy: First-line or subsequent-line targeted treatment under specialist oncology guidance

Prescription Status: Prescription-only oncology medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from light and moisture

Product Description

Geftinat 250 mg is a generic gefitinib tablet used as targeted therapy in selected adults with advanced or metastatic
non-small cell lung cancer (NSCLC). Many NSCLC tumours, especially adenocarcinomas, carry activating EGFR mutations that make cancer cells strongly dependent on
EGFR signalling for growth and survival. Geftinat 250 mg gefitinib tablets are designed to inhibit this pathway and help slow disease progression in EGFR-mutation–positive lung cancer
under the supervision of an experienced oncology team.

Each Geftinat tablet contains 250 mg gefitinib, the standard oral dose used in most gefitinib protocols worldwide.
The convenient 1 pack / 30 tablets presentation usually corresponds to about one month of once-daily treatment, allowing patients and caregivers to align
Geftinat orders with monthly clinic visits and imaging. As a generic gefitinib 250 mg product, Geftinat contains the same active ingredient and strength as the originator brand,
while often being more accessible in USD for long-term targeted therapy.

Geftinat 250 mg gefitinib tablets are normally prescribed only after molecular testing has confirmed that the tumour carries a sensitising EGFR mutation.
In some settings, Geftinat gefitinib is used as first-line systemic therapy in EGFR-positive NSCLC; in others it is given after chemotherapy, depending on current guidelines.
Generic Meds Mart does not decide whether you should receive gefitinib; we supply Geftinat 250 mg in the strength and quantity that match your written treatment plan.

Key Uses

Geftinat 250 mg gefitinib tablets are typically used under specialist supervision for:

• Advanced or metastatic non-small cell lung cancer (NSCLC), usually adenocarcinoma, with documented sensitising EGFR mutations
• First-line targeted therapy in EGFR-mutation–positive NSCLC where gefitinib is recommended by national or international guidelines
• Subsequent-line targeted therapy in selected patients whose disease remains suitable for EGFR inhibitor treatment after previous systemic therapy

Your oncologist will decide whether Geftinat 250 mg is appropriate based on mutation status, previous treatments, performance status and co-existing illnesses.

How Gefitinib Works in Chemotherapy

Gefitinib is a targeted anticancer medicine from the class of EGFR tyrosine kinase inhibitors.
Unlike classic cytotoxic chemotherapy, Geftinat gefitinib does not directly damage DNA. Instead, it selectively blocks the intracellular tyrosine kinase activity of the
epidermal growth factor receptor (EGFR), which is a critical driver of growth in many EGFR-mutated tumours.

In EGFR-positive NSCLC, constitutively active EGFR triggers downstream signalling through pathways such as RAS/RAF/MEK/ERK and PI3K/AKT, promoting tumour cell proliferation and survival.
By binding to the ATP-binding site of the EGFR tyrosine kinase, Geftinat 250 mg reduces receptor phosphorylation and interrupts these signals.
This deprives tumour cells of key proliferative and anti-apoptotic stimuli, so they are more likely to slow growth or undergo programmed cell death.

Because EGFR is also expressed in normal skin and gastrointestinal epithelium, gefitinib therapy can lead to characteristic side effects such as rash and diarrhea,
which require regular monitoring and supportive care.

Dosage & Administration

The dose and schedule of Geftinat 250 mg must always follow your oncology team’s instructions and current guidelines.
In many protocols, the usual adult dose is one Geftinat 250 mg tablet taken once daily, but only your treating specialists can confirm the correct regimen and duration.

• Take Geftinat tablets once daily at roughly the same time each day, with a glass of water.
• Swallow Geftinat 250 mg whole; do not crush, split or chew the tablet unless your pharmacist gives specific instructions.
• Follow your clinic’s advice on taking gefitinib with or without food and aim for a consistent daily routine.
• Do not change your daily dose, interrupt therapy or take extra tablets without clear guidance from your oncology team.
• If you miss a dose, follow the written instructions from your treatment centre; do not double the next dose unless your doctor tells you to.

Regular clinic visits, blood tests and imaging help your doctors assess response and decide whether your dose of Geftinat 250 mg gefitinib should continue or be adjusted.

Precautions

Before starting Geftinat 250 mg gefitinib tablets, inform your healthcare team about your full medical history and all prescription medicines, over-the-counter products and herbal supplements you use.
Key precautions include:

• Pre-existing liver disease or abnormal liver function tests
• History of interstitial lung disease, pulmonary fibrosis or chronic lung conditions
• Use of strong CYP3A4 inducers or inhibitors that may alter gefitinib blood levels
• Use of gastric acid–reducing medicines that can affect gefitinib tablet absorption
• Pregnancy or breastfeeding; Geftinat gefitinib is not recommended and may harm an unborn baby

Men and women of reproductive potential are usually advised to use reliable contraception during and for a period after Geftinat 250 mg therapy, as directed by their oncologist.

Gefitinib Side Effects

Common side effects

Common side effects of Geftinat 250 mg gefitinib tablets may include:

• Acne-like skin rash on the face, scalp and upper torso
• Dry skin, itching or mild redness
• Diarrhea or loose stools
• Nausea, occasional vomiting or reduced appetite
• Mild mouth sores or irritation in the mouth or throat
• Fatigue or a general feeling of low energy
• Mild elevations in liver enzymes on blood tests

These effects are often manageable with supportive care, dermatologic treatments and, when necessary, dose interruptions or adjustments as decided by your oncology team.

Serious side effects

Less common but serious side effects of gefitinib require urgent medical attention and may include:

• New or rapidly worsening shortness of breath, cough and fever suggesting interstitial lung disease or severe pneumonitis
• Signs of serious liver injury: yellowing of the skin or eyes, dark urine, pale stools, persistent upper abdominal pain
• Severe or prolonged diarrhea leading to dehydration and dizziness
• Severe skin reactions with blistering, peeling or painful widespread rash
• Sudden chest pain, severe breathlessness or other acute symptoms suggesting cardiovascular or pulmonary complications

If you experience any of these symptoms while taking Geftinat 250 mg, seek emergency medical care immediately and contact your oncology team.

Storage

• Store Geftinat 250 mg gefitinib tablets at room temperature, preferably below 25 °C.
• Keep tablets in their original blisters and outer carton, protected from moisture and light.
• Keep all anticancer medicines out of the sight and reach of children and pets.
• Do not use Geftinat after the expiry date printed on the packaging.

Ask your pharmacist or oncology centre how to safely dispose of unused or expired Geftinat gefitinib tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart provides safe, structured access to key oncology medicines such as
Geftinat 250 mg gefitinib tablets at transparent prices in USD.
We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a verifiable export record.

When you buy Geftinat online from Generic Meds Mart, you benefit from:

• Original gefitinib 250 mg blisters and cartons from licensed suppliers
• Discreet, plain outer packaging for international delivery
• Tracked shipping options to many destinations
• Clear, structured information about Geftinat gefitinib tablets to support discussions with your oncology team
• Support for ordering, payment and delivery questions

Order Now

Geftinat 250 mg gefitinib tablets are prescription-only targeted anticancer medicines and must be used strictly under specialist supervision.
Before you order Geftinat online, ensure your oncologist has confirmed an EGFR-mutation–positive tumour, recommended gefitinib as part of your treatment plan and specified the daily dose and expected duration.

Select Geftinat 250 mg (1 pack / 30 tablets), choose the quantity that matches your written plan, add it to your cart and complete the secure checkout on Generic Meds Mart.
Your order will be processed, packed discreetly and shipped with tracking where available. All treatment decisions and dose adjustments must remain with your healthcare team.

Erlocip Erlotinib – 150 mg (1 pack / 30 tablets)

At a Glance

Brand name: Erlocip

Generic name: Erlotinib hydrochloride

Active ingredient: Erlotinib

Strength & pack size: Erlocip 150 mg (1 pack / 30 tablets)

Dosage form: Oral film-coated tablets

Main indication: Advanced or metastatic non–small cell lung cancer (NSCLC) and selected pancreatic cancer indications

Therapeutic class: EGFR tyrosine kinase inhibitor

Use in therapy: Targeted first-line or subsequent EGFR-directed therapy in NSCLC and other approved settings

Prescription status: Prescription-only anticancer medicine

Supplied by: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from moisture and light

Product Description

Erlocip 150 mg tablets are a generic erlotinib hydrochloride medicine used as targeted therapy for certain advanced cancers.
Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) that interferes with signalling pathways driving tumour growth,
particularly in advanced non–small cell lung cancer (NSCLC).
Erlocip 150 mg (1 pack / 30 tablets) provides a convenient once-daily strength of erlotinib for patients whose oncologists have recommended EGFR-directed treatment.

Erlocip erlotinib tablets are often used in locally advanced or metastatic NSCLC, especially when tumours harbour activating
EGFR mutations that make them sensitive to EGFR tyrosine kinase inhibition. In some settings,
erlotinib tablets may also be used in pancreatic cancer, according to recognised protocols and specialist judgement.
Because Erlocip is a generic erlotinib product, it contains the same active ingredient as branded erlotinib while offering more accessible pricing in USD.

Each Erlocip 150 mg tablet contains erlotinib hydrochloride equivalent to 150 mg of erlotinib.
Tablets are taken by mouth, usually once daily, and your oncologist may instruct you to take Erlocip on an empty stomach or to avoid certain foods and medicines that alter absorption.
When you buy Erlocip 150 mg online from Generic Meds Mart, you receive medicines from licensed manufacturers and authorised distributors operating under recognised GMP standards.
Discreet outer packaging protects your privacy, while original blisters and cartons preserve full product information.

This Erlocip 150 mg (1 pack / 30 tablets) product is intended only for patients already under specialist oncology care who have been advised to use
erlotinib therapy. Generic Meds Mart does not diagnose cancer or change treatment plans;
the information on this page supports informed discussions with your oncology team about access to generic erlotinib tablets.

Key Uses

Erlocip 150 mg erlotinib tablets are typically used for the following indications under specialist supervision:

• Treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC), especially in EGFR mutation–positive tumours
• First-line, maintenance or subsequent therapy in selected NSCLC patients where EGFR TKI treatment is recommended
• Treatment of certain advanced pancreatic cancer cases, in combination with other agents, where erlotinib is indicated

Your oncologist will determine whether Erlocip 150 mg is appropriate, specify the daily dose and decide how long
erlotinib treatment should continue.

How Erlotinib Works in Chemotherapy

Erlotinib is a targeted anticancer agent often grouped within modern systemic chemotherapy and targeted therapy regimens.
Erlocip contains erlotinib, an EGFR tyrosine kinase inhibitor (TKI) that blocks signalling from the epidermal growth factor receptor.
In many NSCLC tumours, activating EGFR mutations cause continuous signalling and uncontrolled cell growth.

Erlocip erlotinib tablets bind to the intracellular tyrosine kinase domain of EGFR and block ATP binding,
disrupting downstream signalling pathways that promote cancer cell proliferation and survival. In tumours that depend heavily on EGFR signalling,
this can lead to tumour shrinkage or stabilisation. Because erlotinib targets a molecular driver of the cancer rather than all rapidly dividing cells,
its side effect profile differs from traditional cytotoxic chemotherapy, but careful monitoring is still required.

EGFR mutation testing is an important part of deciding whether Erlocip erlotinib is appropriate.
Your oncologist will interpret test results and determine whether an EGFR TKI such as Erlocip fits your overall treatment plan.

Dosage & Administration

Erlocip 150 mg erlotinib tablets must always be taken exactly as prescribed by your oncologist.
Daily dosing, timing and duration of therapy depend on your diagnosis, tumour characteristics, other medicines and response to treatment.

• Take Erlocip tablets by mouth with water; your doctor may instruct you to take them on an empty stomach or at specific times relative to meals.
• Swallow erlotinib tablets whole without crushing, splitting or chewing unless your doctor or pharmacist provides specific instructions.
• Take Erlocip 150 mg once daily at approximately the same time each day, unless your oncologist advises otherwise.
• Do not change your dose, skip doses or stop taking Erlocip without clear guidance from your oncology team.
• If you miss a dose, follow your doctor’s instructions; do not double the next dose unless specifically advised.

Your oncologist will schedule regular visits, blood tests and imaging studies to monitor your response to
Erlocip erlotinib therapy and to adjust the treatment plan if necessary.

Precautions

Before starting Erlocip 150 mg, inform your doctor about your full medical history and all medicines, supplements or herbal products you use. Important considerations include:

• History of lung diseases such as interstitial lung disease, pulmonary fibrosis or other chronic lung conditions
• Liver disease, kidney impairment or significant cardiovascular disease
• Previous severe skin reactions or serious gastrointestinal problems
• Use of medicines that alter stomach acidity (proton pump inhibitors, H2 blockers, antacids)
• Use of CYP3A4 inhibitors or inducers, certain antibiotics, antifungals or antiepileptics that may interact with erlotinib
• Use of anticoagulants, especially warfarin, which may require closer monitoring during Erlocip erlotinib therapy

Erlotinib may not be suitable during pregnancy, and effective contraception is usually recommended during treatment and for a period afterwards, as advised by your doctor.
Breastfeeding is often discouraged while taking Erlocip. Your oncology team will explain which precautions and monitoring tests apply to you.

Erlotinib Side Effects

Common side effects

Many patients experience side effects when starting Erlocip erlotinib tablets, especially during the first weeks of therapy. Common side effects may include:

• Acne-like skin rash, often on the face, scalp or upper trunk
• Dry, itchy or sensitive skin, sometimes with increased sun sensitivity
• Diarrhea or loose stools
• Mild nausea, vomiting or stomach discomfort
• Reduced appetite and weight loss
• Fatigue or general weakness

These effects are often manageable with supportive care, skin protection, diet adjustments or dose modifications.
You should report persistent or troublesome symptoms to your oncology team.

Serious side effects

Some side effects of erlotinib are less common but serious and require urgent medical attention. Serious reactions may include:

• New or worsening shortness of breath, cough or fever that may indicate interstitial lung disease or severe lung inflammation
• Severe or persistent diarrhea with signs of dehydration, such as dizziness, fainting or reduced urine output
• Severe abdominal pain, black or bloody stools or vomiting blood, which may indicate gastrointestinal perforation or bleeding
• Signs of liver problems, including yellowing of the skin or eyes, dark urine, pale stools or intense upper abdominal pain
• Severe skin reactions with widespread rash, blistering, peeling or involvement of the mouth, eyes or other mucous membranes

If you experience any of these serious symptoms while taking Erlocip 150 mg, seek immediate medical care and contact your oncology team as soon as possible.

Storage

• Store Erlocip 150 mg tablets at room temperature, usually below 25 °C, in a dry place away from direct sunlight and excess heat.
• Keep the tablets in their original blisters and carton until use to protect them from moisture and light.
• Keep erlotinib tablets out of the sight and reach of children and pets.
• Do not use the medicine after the expiry date printed on the packaging.

Ask your pharmacist or follow local regulations for safe disposal of unused or expired Erlocip erlotinib tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on providing reliable access to essential oncology medicines such as
Erlocip 150 mg erlotinib tablets at fair prices in USD.
We work only with licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a documented export track record.

When you buy Erlocip 150 mg online from Generic Meds Mart, you benefit from:

• Competitive pricing on generic erlotinib tablets compared with many local pharmacies
• Discreet, plain packaging designed to protect your privacy during shipping
• Tracked international delivery options to many destinations
• Clear, structured product information to support discussions with your oncologist
• Customer support available to assist with ordering, payment and shipping questions

Our goal is to help you maintain continuity of prescribed targeted therapy with transparent conditions and professional handling of each order.

Order Now

Erlocip 150 mg erlotinib tablets are prescription-only anticancer medicines and must be used strictly under the supervision of an oncologist.
Before you order Erlocip 150 mg online, ensure that you have a valid prescription or written treatment plan specifying erlotinib, the 150 mg strength and the intended duration of therapy.

Select Erlocip 150 mg (1 pack / 30 tablets), choose the appropriate quantity, add Erlocip to your cart and complete the secure checkout process.
Your order will be processed, packed discreetly and shipped with tracking where available.

Generic Meds Mart does not provide diagnosis or personalised medical advice. All treatment decisions, dose changes and monitoring remain the responsibility of your oncology team.

Q6: Is Erlocip 150 mg the same as Tarceva (Generic Tarceva)?
Erlocip 150 mg is Generic Tarceva — it contains the same active ingredient (erlotinib) as Tarceva. It’s used for the same purpose at the same strength, while differences may be in manufacturer, inactive ingredients (excipients), tablet appearance, and packaging. If you’re switching between products, confirm the substitution with a qualified healthcare professional.